Skip to main content
. 2017 Jan 18;37(3):637–647. doi: 10.1523/JNEUROSCI.2110-16.2016

Figure 4.

Figure 4.

TREM2 deficiency reduces myeloid cell proliferation late in disease progression. Mice were injected with 10 mg/kg BrdU intraperitoneally every 24 h for 72 h and killed 24 h after the last injection. a, b, BrdU immunohistochemistry was used to identify proliferating cells in 2-month-old (a) and 8-month-old (b) APPPS1;Trem2−/− and APPPS1;Trem2+/+ mice. c, Number of BrdU+ Iba1+ double-positive cells was quantified in the cortex of 2-month-old (WT, n = 1 M/2 F; KO, n = 1 M/1 F) and 8-month old (WT, n = 3 M/1 F; KO, n = 5 M/3 F) APPPS1;Trem2−/− and APPPS1;Trem2+/+ mice. There were no significant differences in the numbers of proliferating myeloid cells in 2-month-old TREM2-deficient mice, but there were significant decreases in 8-month-old APPPS1;Trem2−/− mice compared with APPPS1;Trem2+/+ controls. d, Brain myeloid cells were isolated from 6- to 9-month-old APPPS1 mice and cells were analyzed by flow cytometry. e, Cells were gated on CD11b and divided into CD45lo and CD45hi cells. f, When the percentage of BrdU+ cells was quantified within that CD45hi population, there were very few proliferating cells (0.43%). g, However, there was a substantial population (7.53%) of proliferating CD45lo cells. ***p < 0.001.